Sugi Predict

Sugi Predict / Compounds / SCHEMBL8564502

SCHEMBL8564502

SCHEMBL8564502

COC(=O)c1c(O)cccc1Cl

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 4/20 0.77
▸ CA1 P00915 4/20 0.77
▸ CA2 P00918 4/20 0.77
▸ CA7 P43166 4/20 0.77
▸ CA9 Q16790 4/20 0.77
▸ CA14 Q9ULX7 4/20 0.77
▸ TSHR P16473 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ POLB P06746 2/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ THRB P10828 1/20 0.47
▸ GAA P10253 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NR4A2 P43354 3/20 0.45
▸ HSP90B1 P14625 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL517538 0.88 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL1519936 0.88 CA12 (1.00) CA12CA1CA2CA7CA9
SCHEMBL852447 0.83 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL485070 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL4627944 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL7671969 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL29445387 0.81 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL4144207 0.81 CA1 (0.77) CA12CA1CA2CA7CA9
SCHEMBL9315569 0.80 CA12 (0.48) CA12CA1CA2CA7CA9
SCHEMBL2339088 0.80 CA12 (0.79) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025061035-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 南京再明医药有限公司 2025-03-27 — — WO disclosed
CN-114380751-B Indanamine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2025-03-07 — — CN disclosed
WO-2024213125-A1 BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF 南京再明医药有限公司 2024-10-17 — — WO disclosed
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-09 — — US disclosed
US-20220144857-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2022-05-12 — — US disclosed
EP-3995497-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE Canon Kabushiki Kaisha (JP) 2022-05-11 — — EP disclosed
CN-114380751-A Indane amine derivatives, preparation method and application thereof 上海辉启生物医药科技有限公司 2022-04-22 — — CN disclosed
CN-114315736-A Indane amine derivatives, preparation method and application thereof 甫康（上海）健康科技有限责任公司 2022-04-12 — — CN disclosed
EP-3903788-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2021-11-03 — — EP disclosed
EP-3747862-A1 ALDH2 ACTIVATOR Eisai R&D Management Co., Ltd. (JP) 2020-12-09 — — EP disclosed
US-20150218096-A1 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2015-08-06 — — US disclosed
US-20150218096-A1 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2015-08-06 — — US disclosed
US-20150218096-A1 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME LLC 2015-08-06 — — US disclosed
EP-2884981-A2 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF Merck Sharp & Dohme Corp. (US) 2015-06-24 — — EP disclosed
WO-2014028589-A2 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2014-02-20 — — WO disclosed
WO-2014026327-A1 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2014-02-20 — — WO disclosed
CN-1898198-A Alpha-hydroxy amides as bradykinin antagonists or inverse agonists MERCK & CO INC (US) 2007-01-17 — — CN disclosed
EP-0863881-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-09-16 — — EP disclosed
WO-1997010219-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-03-20 — — WO disclosed
EP-0700907-A1 Process for producing pyrimidine derivative SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1996-03-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144857-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE SPIN4, OR10J3, SPIN1 CA12 2154/4885CA1 1352/4885CA2 2406/4885
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND ZC3HAV1, ZC3HAV1L, IL5 CA12 3982/4885CA1 4449/4885CA2 2410/4885
US-20150218096-A1 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF RORB, RORA, RORC CA12 1627/4885CA1 978/4885CA2 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.